
DWTX Stock Forecast & Price Target
DWTX Analyst Ratings
Bulls say
Dogwood Therapeutics is expected to continue its positive momentum as it advances its product pipeline focused on treating chronic neuropathic pain and neuropathy. This is supported by a 12-month price target of $12.00 per share based on a risk-adjusted net present value analysis and potential risks that include clinical, regulatory, commercial, collaboration, financial, and intellectual property factors. With a healthy rNPV of $374M and significant pro forma net cash of $17.9M, investors have a strong reason to be optimistic about Dogwood Therapeutics's future prospects.
Bears say
Dogwood Therapeutics is a development-stage biopharmaceutical company that is yet to generate any revenues and is projected to continue incurring losses in the near future with a current net loss of $0.15 per share. With limited cash and a focus on developing a single drug candidate, SP16, with no clear indication of success, the company's financial prospects remain uncertain, warranting a negative outlook.
This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
DWTX Analyst Forecast & Price Prediction
Start investing in DWTX
Order type
Buy in
Order amount
Est. shares
0 shares